Close this search box.
Close this search box.

T2Candida Panel

Faster targeted therapy leads to reduced costs and improved outcomes

The T2Candida® Panel is the first and only FDA-cleared diagnostic test for the detection of sepsis-causing fungal pathogens, direct from whole blood. Species identification is provided within 3 to 5 hours of the first blood draw and independent of a positive blood culture, often before the second dose of antimicrobials is administered.

T2Candida is most clinically impactful for patients in any of these conditions1:

  • Admitted to the ICU
  • Have febrile neutropenia
  • Have septic shock
  • Have an LVAD and evidence of active infection
  • In ICU at high risk for candidemia

Better patient outcomesCandida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, by providing results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity. One model estimates that early diagnosis with T2Candida may prevent an estimated 60% of Candida-related deaths.4

Unprecedented speed and accuracy: The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours5, while other methods require a positive blood culture before the identification of Candida species. The T2Candida panel can detect species at concentrations of just 1-3 CFU/mL 5, a considerable improvement over blood cultures that have a low sensitivity of only 60% for Candida species and are susceptible to interference from antimicrobials6.  Blood cultures have a median time to positivity of 2-3 days and negative results determined after 5 days of inactive growth. T2Candida empowers clinicians to make important clinical decisions sooner.

Faster targeted therapy: Studies have shown that the time to targeted therapy greatly impacts patient outcomes and reduces mortality rates, with corresponding reductions in healthcare costs from shorter length of stay, and a reduction in the overuse of antifungals. It’s estimated that the T2Candida Panel can save roughly $27,000 per patient due to faster results and subsequent targeted therapy.4 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster targeted therapy for patients in clinical care for more than 24 hours.8,9

Improved stewardship and pharmacy savings: Hospitals – including Lee Health,9 Huntsville Hospital,10 and University of Pittsburgh Medical Center11 – have reported antifungal savings from negative test results, which can more than offset the full cost of the test.

Watch T2Candida at work.

Contact us to request a demo of the T2Candida Panel!


1. Clancy CJ and Nguyen MH. Diagnostic Microbiology and Infectious Disease, 2018
2. Morrell M, et al. Antimicrobial Agents and Chemotherapy, 2005
3. Garey KW, et al.  Clinical Infectious Diseases, 2006
4. Bilir SP, et al. Future Microbiol, 2015
5. Mylonakis E, et al. Clinical Infectious Diseases, 2015
6. Clancy CJ and Nguyen MH. Clinical Infectious Diseases, 2013
7. Beyda ND, et al. Journal of Clinical Microbiology, 2018 
8. Wilson NM, et al. The Journal of Antimicrobial Stewardship, 2017
9. Patch ME, et al. Journal of Antimicrobial Chemotherapy, 2018
10. Edwards JD. Oral Presentation, ASM Microbe, 2017
11. Shields R, et al. Poster Presentation, IDWeek, 2018


Sensitivity: 91%5 
Specificity: 99%5

Candida albicans
Candida tropicalis
Candida krusei
Candida glabrata
Candida parapsilosis

1-3 CFU/mL LoD